Frost & Sullivan provides pharmaceutical industry outlook 2003
FDA Approves Lenacapavir for Prevention of HIV
The decision makes the therapy the first and only twice-yearly option available in the United States for PrEP.
The Potential Impact Pharmaceutical Tariffs May Have on Pharmacies
Marta Wosinska, PhD, and Joey Mattingly, PharmD, MBA, PhD, joined Drug Topics to help us understand how pharmaceutical tariffs could potentially impact the pharmacy industry.
Pneumococcal Hemolytic Uremic Syndrome Increased Among Children Over Last 15 Years
Researchers explored the incidence of pneumococcal hemolytic uremic syndrome in children living in Sweden from January 2009 to December 2024.
Scripted for Her: Addressing Preconception Health Through MTM
In this episode, Natalie DiPietro Mager, PharmD, PhD speaks with David Bright, PharmD, MBA, professor at Ferris State University College of Pharmacy.
Mark Cuban Cost Plus Drugs, 9amHealth Collaborate to Make Obesity Medications Affordable
The program will include branded obesity glucagon-like peptide-1 medications, which will have a transparent monthly cost.
Atogepant Shows Superiority Over Topiramate for Migraine Prevention
Topline results from a phase 3 trial showed 64.1% of patients on atogepant achieved a 50% or greater reduction in mean monthly migraine days during months 4 to 6.
